Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 févr. 2016 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

NEW YORK, Feb. 4, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 18th Annual BIO CEO & Investor...
05 janv. 2016 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 34th Annual J.P. Morgan...
22 déc. 2015 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Opening of SL-801 IND

NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the opening of its SL-801 Investigational New Drug (IND) application and initiation of a broad...
07 déc. 2015 11h23 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Presents Clinical Update From Ongoing SL-401 Pivotal BPDCN Trial at the American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the presentation of positive clinical data, including high response rates, from the lead-in and...
04 déc. 2015 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Five Presentations, Including SL-401 Clinical Update From Ongoing Pivotal BPDCN Trial, at the Upcoming American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 4, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401 and SL-801 will be the subject of five poster presentations at the 2015 American...
03 déc. 2015 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference

NEW YORK, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Oppenheimer 26th Annual Healthcare...
06 nov. 2015 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2015 Financial Results

NEW YORK, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended September 30, 2015. Ivan Bergstein, M.D., Stemline's Chief...
05 nov. 2015 09h29 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Five Presentations at the American Society of Hematology (ASH) Annual Meeting; SL-401 Poster Will Include Clinical Data From Lead-In and Ongoing Expansion Stages of BPDCN Pivotal Trial

NEW YORK, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it will present results from clinical and preclinical studies, including updated data from its...
02 nov. 2015 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces SL-401 Receives EU Orphan Drug Designation for Treatment of BPDCN

NEW YORK, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the European Medicines Agency (EMA) has granted Orphan Drug designation to SL-401 for the...
28 sept. 2015 08h00 HE | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Ladenburg Thalmann 2015 Healthcare Conference

NEW YORK, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Ladenburg Thalmann 2015 Healthcare...

Page précédente